China Biologic Products Holdings Inc (CBPO) - Comprehensive Stock Analysis & Investment Research
Deep dive into China Biologic Products Holdings Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
Understanding Company Overview
What this section covers: Essential business information about China Biologic Products Holdings Inc, including sector classification, industry positioning, and organizational structure.
How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.
For China Biologic Products Holdings Inc: China Biologic Products Holdings Inc operates in the Manufacturing sector, establishing it as a mid-cap growth opportunity.
China Biologic Products Holdings Inc (Stock Symbol: CBPO) is a leading company in the Manufacturing sector , specifically operating within the Biological Product (except Diagnostic) Manufacturing industry.
The organization employs approximately 2269 professionals worldwide and operates under the strategic leadership of CEO David Gao.
The company has established itself as a growing mid-cap opportunity with strong fundamentals.
Understanding Financial Performance
What these metrics mean: Key financial indicators showing China Biologic Products Holdings Inc's revenue scale, profitability, market value, and shareholder returns.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For China Biologic Products Holdings Inc: With $514M in annual revenue and 27.1% net margin, the company demonstrates exceptional profitability.
Annual Revenue: $514 million generating a 27.1% net profit margin .
Market Capitalization: $4680 million - Classified as a mid-cap growth stock with balanced risk-reward profile.
Return on Equity (ROE): 7.9% - Below-average shareholder return efficiency, indicating areas for operational improvement.
Understanding AI Stock Predictions
What these predictions mean: AI-powered forecasts for China Biologic Products Holdings Inc stock using machine learning algorithms trained on historical market data and technical indicators.
How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.
For China Biologic Products Holdings Inc: Unlock premium access to view detailed AI predictions and price targets.
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for China Biologic Products Holdings Inc stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Understanding Market Position
What this analysis covers: China Biologic Products Holdings Inc's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.
How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.
For China Biologic Products Holdings Inc: Strong free cash flow generation demonstrates solid operational efficiency.
China Biologic Products Holdings Inc strategically competes in the highly dynamic Biological Product (except Diagnostic) Manufacturing marketplace, establishing itself as a promising mid-cap growth opportunity with strong fundamentals and expanding market share .
The company demonstrates robust operational efficiency through strong free cash flow generation of $244 million annually, complemented by impressive 120.6% year-over-year cash flow growth.
The company maintains a healthy 64.9% gross margin, indicating strong pricing power and operational efficiency.